256 results about "Amniotic liquid" patented technology

A source of multipotent amniotic fluid / fetal stem cells (MAFSCs) is disclosed. MAFSC are of fetal origin and have a normal diploid karyotype. These cells are characterized by the following cell surface markers: SSEA3, SSEA4, Tra-1-60, Tra-1-81, Tra-2-54, HLA class I, CD13, CD44, CD49b, CD105 and are distinguished by the absence of the antigen markers CD34, CD45, and HLA Class II, but are distinguished from mouse embryonic stem cells in that these cells do not express the cell surface marker SSEA1. MAFSC express the stem cell transcription factor Oct-4. MAFSC cells can be propagated for an indefinite period of time in continuous culture in an undifferentiated state. The MAFSCs have the ability to differentiate in culture in a regulated manner, into three or more subphenotypes. Cells can then be differentiated into endodermal, mesodermal and ectodermal derived tissues in vitro and in vivo. A method for isolating, identifying, expanding and differentiating MAFSCs is disclosed.

A method of treating diabetes in a mammalian subject is carried out by: (a) providing mammalian amniotic fluid stem cells, and then (b) administering the cells to the subject in an amount effective to treat diabetes. Optionally, the cells may be differentiated into pancreatic-like cells or at least treated to initiate subsequent differentiation into-pancreatic-like cells, prior to administration.

The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal / fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns a comprehensive proteomic analysis of human amniotic fluid (AF) and cervical vaginal fluid (CVF), and the correlation of characteristic changes in the normal proteome with various pathologic maternal / fetal conditions, such as intra-amniotic infection, pre-term labor, and / or chromosomal defects. The invention further concerns the identification of biomarkers and groups of biomarkers that can be used for non-invasive diagnosis of various pregnancy-related disorders, and diagnostic assays using such biomarkers.

The invention relates to a method for the early non-invasive diagnosis of fetal aneuploidy. In particular, the invention concerns the diagnosis of fetal aneuploidy by identifying protein expression patterns characteristics of fetal aneuploidy in a maternal biological fluid, such as maternal serum or amniotic fluid.

There is provided a composition for healing burns and wounds in mammals, which contains a cromolyn compound or the combination of a cromolyn compound and hyaluronic acid a corticosteroid.Advantageously, elements found in amniotic fluid are also included.

The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal / fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns the identification of the proteome of amniotic fluid (multiple proteins representing the composition of amniotic fluid) and the correlation of characteristic changes in the normal proteome with various pathologic maternal / fetal conditions, such as intra-amniotic infection, or chromosomal defects.

Improved methods for sport injury surgeries are described. The improvement includes covering a damaged site of fascia with at least one of an amniotic fluid and a construct for use in surgical repair of the sport injury prior to wound closing. The construct contains an allograft comprising at least one layer of human amnion and chorion tissues and the construct has a size and shape suitable for covering the damaged site of fascia. The method improves fascial membrane repair, reduces complications and recovery time of sport injury surgeries.

SNAP-25 (synaptosomal associated protein) is purified from cerebrospinal or amniotic fluid for immunoassay and quantitation. Quantitation of these proteins is useful in the diagnosis and monitoring of brain disorders and diseases such as schizophrenia and Alzheimer's.

The present invention provides a bodily fluid-testing composition for the determination and quantification of a specific ion concentration exceeding a pre-set threshold in a tested fluid, in which an ion oppositely charged to the ion in the bodily fluid is used to compete with an indicator reagent in order to compensate for variability in specific binding of the bodily fluid ions. The present invention further provides an article for monitoring of bodily fluids comprising a substrate and an absorbent material for absorbing the bodily fluid. The substrate includes a composition suitable for identification of a specific ion concentration in a tested fluid. The article can be used to indicate the presence of abnormal ammonium concentration in human urine, amniotic fluid leakage, or biogenic secretions associated with bacterial vaginosis, parasite infections, or deficiency of lactobacillus population, without giving a false positive result.

The invention provides an exosome separation method and a separation device thereof. The exosome separation method comprises the steps: firstly filtering or centrifuging blood, urea, saliva, cerebrospinal fluid, milk, ascetic fluid or amniotic fluid to remove impurities larger than 1 micrometer; then utilizing an even pore diameter anodized aluminum oxide film with the pore diameter correspondingto the diameter size of the exosome to filter, collecting filtrate or exosome on the even pore diameter anodized aluminum oxide film to obtain required exosome. The exosome separation device comprisesa membrane filter with the even pore diameter anodized aluminum oxide film as a filter membrane. By means of the separation method and the separation device thereof disclosed by the invention, the exosome can be simply and efficiently separated, the different sizes of exosome can be cut out and classified, and the different sizes of exosome can be respectively and correspondingly analyzed, researched and applied.

The invention discloses a probe and a kit for detecting pseudo-hypertrophic muscular dystrophy. The probe for detecting pseudo-hypertrophic muscular dystrophy comprises nucleic acid sequences shown by SEQ NO:1-SEQ ID NO:546, and the kit for detecting pseudo-hypertrophic muscular dystrophy comprises nucleic acid sequences shown by SEQ ID NO:1-SEQ ID NO:546. The probe and the kit for detecting pseudo-hypertrophic muscular dystrophy can be used for detecting complete mutation information of DMD genes, including exon deletion / repetition and point mutation, have the advantages of completeness, rapidness, accuracy and appropriate price, and can be used for solving the problems of DMD molecular diagnosis; the kit disclosed by the invention is suitable for detection of various tissue samples of muscle, blood, amniotic fluid and the like, can detect pathogenic mutation of exons and introns as well as known mutations and unreported pathogenic mutations, and is also used for detecting whether patient genotypes are corrected or not after stem cell therapy.

The invention relates to an amplification composition for detecting abnormal number of chromosomal aneuploid and a rapid detection kit, and belongs to the technical field of biology. The amplification composition can be used for amplification detection of STR sites related to 8 21# chromosomes, 6 18# chromosomes, 6 13# chromosomes and 3 X chromosomes and amplification detection of four amelo; all sites can be amplified by a quantitative fluorescent PCR (QF-PCR) technology, so as to detect the abnormal number of 21, 18, 13, X and Y chromosomal aneuploid. According to the kit, detection cycle is short, so the result can be obtained within 5 hours after obtaining the sample; the sensitivity is high; DNA at nanogram level, which is equal to DNA contained in 100 cells, is needed for each detection, so few samples are needed; 1 to 2ml of amniotic fluid can be collected to meet the demand; due to high sensitivity, a chimera containing more than 10% of trisomies can be detected.

The present invention relates to a method of predicting the risk of a subject developing a cardiovascular event, comprising determining the presence of a biomarker that is indicative of the risk of developing a cardiovascular event in exosomes from the subject. The exosomes are suitably isolated from a body fluid selected from serum, plasma, blood, urine, amniotic fluid, malignant ascites, bronchoalveolar lavage fluid, synovial fluid, breast milk, saliva, in particular serum. The biomarker is selected from the proteins Vitronectin, Serpin F2, CD14, Cystatin C, Plasminogen, Nidogen 2 or any combination of two or more of these proteins.

The invention discloses four cell types which have wide heteroplastic transplantation application prospect and can be effectively induced into induced pluripotent stem (iPS) cells. The origins of three cell types are placental tissue, namely amnion mesenchymal cell, chorion mesenchymal cell and umbilical cord mesenchymal cell; and the origin of the other one is amniotic fluid cell. Besides, the invention also discloses an induction reprogramming method for producing cells capable of producing induced pluripotent stem (iPS) cells by efficient induction, including the following steps: cDNA containing pluripotent stem cell factor is respectively introduced into the four primary culture cells; the four primary cells in which cDNA is introduced are respectively cultured on appropriate culture mediums, primary iPS is obtained and then quality of iPS is optimized on appropriate culture mediums, and cloning of pluripotent stem cell can be primarily evaluated. In the invention, three mesenchymal cells of placenta origin and amniotic fluid cell all can be induced into iPS, wherein the chorion mesenchymal cell is compared with fibroblast, efficiency of induction reprogramming is improved by over 100 times, efficiency is about 2.3%, and the efficiency is slightly higher than that of horny cell; and a means which is more effective and more pertinent is provided for building disease model, screening drug and controlling oriented differentiation.

The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal / fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns the identification of the proteome of amniotic fluid (multiple proteins representing the composition of amniotic fluid) and the correlation of characteristic changes in the normal proteome with various pathologic maternal / fetal conditions, such as intra-amniotic infection, or chromosomal defects.

Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed, and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and / or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.

The present invention provides improved methods of prenatal diagnosis, monitoring, screening and / or testing. The invention is based, at least in part, on the discovery that amniotic fluid is a rich source of cell-free fetal RNA. Methods of isolation and analysis of fetal RNA are described, that can lead to information about fetal gene expression that is not available by other techniques. The inventive systems allow for a more comprehensive determination of a living human fetus' health, growth and development and for the prenatal diagnosis of a variety of diseases and conditions.

The present invention relates to the isolation, propagation and use of prenatal stem cells. The cells are CD105 negative. In certain embodiments the cells are also SSEA-4 positive or negative, and c-kit negative. The cells may be isolated from a prenatal sample, for instance third trimester amniotic fluid or placental membrane. The cells may be combined with a biologically compatible solution or a biologically compatible matrix and utilized to treat a human subject. The invention also contemplated enriched populations of prenatal stem cells. The enriched cell population may be propagated in the appropriate culture medium and the resulting progeny cells utilized therapeutic applications.

The invention discloses a kit for non-invasively detecting whether a fetal chromosome to be tested is aneuploid and a special probe set thereof. The probe set includes 500 specific probes. Each specific probe includes a DNA fragment 2. The nucleotide sequence of the DNA fragment 2 of the 500 specific probes is sequentially as shown in a sequence 1 from 5' end 16-93rd sites of the sequence table toa sequence 500 from 5' end 16-93rd sites of the sequence table. The experiment proves that the kit provided by the invention can detect whether NO.13 fetal chromosome, NO.18 fetal chromosome, NO.21 fetal chromosome and fetal sex chromosome to be tested are aneuploid, and the detection result is completely consistent with the detection result of the amniotic fluid gold standard. The kit has important application value.

The invention relates to a tool and a method for diagnosing premature rupture of a membrane by continuous monitoring, which are applicable to household. The tool consists of an upper isolation filter layer, a medium testing system and a lower absorption layer, wherein the testing system consists of an A-type solid-phase vector containing urease and pH indicator and a B-type solid-phase vector containing the pH indicator. The diagnosing method comprises the following steps that: when fluid from the lower body simultaneously soaks two solid-phase vectors, and color development on the A-type solid-phase vector and the B-type solid phase vector has differences, the fluid is urine; and when the color development and color gradation on the A-type solid-phase vector and the B-type solid-phase vector are completely same, the fluid is amniotic fluid. The tool and the method have the advantages of simple operation, higher sensitivity and specificity, continuous detection of discontinuous leakage of the amniotic fluid and real-time property.

The invention discloses an amniotic fluid detection indicator composition, preparation thereof and a corresponding amniotic fluid detection pad. The amniotic fluid detection indicator composition is used by taking one or two of water, ethyl alcohol, acetone and N,N-dimethylformamide as a solvent or solvents, taking one or more than one of pulullan, sodium alginate, ethyl cellulose and sodium carboxymethylcellulose as a film-forming agent or film-forming agents, taking dioctyl phthalate as a plasticizer, taking ethylene glycol, glycerol and glycol ethylene ether as wetting agents, taking bromothymol blue sodium salt, bromoxylenol blue, sodium alizarine sulfonate and bromcresol purple as indicators, preparing an amniotic fluid detection indicator at the normal temperature, then coating a medical sanitary pad with the amniotic fluid detection indicator, and drying the medical sanitary pad to prepare an amniotic fluid detection pad. The amniotic fluid detection indicator composition is convenient to use, not easy to decolor and more easily acceptable to patients, and is capable of distinguishing amniotic fluid and urine; the whole process is simple to operate; the large-scale production is easy to implement.

Method for gentle separation of viable sporadic cells from body fluids such as blood, from malignant effusions, bronchoalveolar lavage fluid, peritoneal lavage fluid and amniotic fluid, based on a filter membrane which is in an intimate contact with an absorbent material. Using the present method it is possible to isolate for example circulating and disseminated tumor cells, endometrial cells and circulating trophoblast cells, allowing subsequent detection, quantification, characterization and especially culturing of said cells. An apparatus for carrying out the method is further disclosed.

The invention provides a kit for detecting genotype of human chromosome 21 STR (short tandem repeat). The kit comprises an amplification reagent and an amplification product detection reagent and mainly contains primers of 12 pairs of fluorescent markers, a molecular weight internal label containing the size of 14 fragments, an allele typing standard product and a quality control product. According to the kit disclosed by the invention, when the kit is used, the required quantity of specimens is small, the diagnosis is fast, and the kit is suitable for villi, amniotic fluid, blood and other tissues, and can be used for not only prenatal diagnosis, but also source analysis of extra chromosomes of a 21-trisomy aborted fetus; the kit can precisely diagnose the genotype and is conductive to presentation of diagnosis result and laboratory quality evaluation; and the kit can further realize fast, accurate, automatic and high-throughput detection of the number of chromosomes 21 and realize quality controllability and standardization of a detection result, and thus has clinical application prospects.

The invention provides porcine body powder. The porcine body powder consists of the following raw materials by weight: 30 to 40 kg of talc powder, 40 to 60 kg of montmorillonite, 5 to 10 kg of boric acid, 3 to 6 kg of salicylic acid, 1 to 3 kg of borneol oil, and 4 to 8 kg of zinc oxide. The invention also provides a preparation method for the body powder. The method comprises the following steps of: (1) crushing the boric acid, the salicylic acid and the zinc oxide to be more than 100 meshes for later use; (2) putting 10 to 15 kg of talc powder into a mixer, putting the borneol oil, and mixing for 20 to 25 minutes in the mixer to obtain a spare material; and (3) putting the montmorillonite, the crushed boric acid, salicylic acid and zinc oxide, the rest talc powder and the spare material of the step (2) into the mixer, mixing for 20 to 25 minutes, discharging and bagging. The porcine body powder is used for protecting the abdomen, the breasts, the rear legs and the hip of a sow during production of the sow, so that postpartum triple syndromes of the sow when the breasts and the vulva of the sow are directly in contact with the ground to infect bacteria are avoided; the amniotic fluid of the whole body of a newly born pig is adsorbed by porcine body powder, so that the survival rate of the newly born pig is improved; and the docking wound of the newly born pig is isolated and protected, so that bacterial infection is reduced.

The invention discloses a parturition-imitating biological heavy metal soil remediation ball. The invention belongs to the technical field of soil remediation. According to the scheme, potassium permanganate powder in an upper exposed ball is continuously decomposed under the action of external illumination; oxygen generated by decomposition can be promoted to enter a splitting repair cylinder; therefore, a sealing film on the outer side of the splitting repair cylinder is ejected open; on one hand, rhizopus culture liquid can be promoted to enter the splitting repair cylinder; meanwhile, oxygen can also provide raw materials for the respiration of rhizopus oryzae; the rhizopus oryzae in the rhizopus oryzae culture liquid can be promoted to be uniformly distributed; on the other hand, oxygen is continuously increased; a lower pre-buried ball can also be broken through extrusion, so that the upper exposed ball, the lower pre-buried ball, the rhizopus culture liquid and a main transmission hose are respectively simulated into a parent body, an embryo, amniotic fluid and an umbilical cord, and the division repair cylinder is promoted to be uniformly distributed in the soil by simulating an embryo development process, so that the soil heavy metal treatment is more sufficient.

The present invention relates to a culture medium for the fetus-derived mesenchymal stem cells in amniotic fluid. More particularly, the present invention relates to a composition for improving skin conditions, comprising the culture medium of fetus-derived mesenchymal stem cells in amniotic fluid as an active ingredient, in which the skin conditions to be improved include whitening, wrinkles, skin damages caused by UV rays or skin lifting. Further, the present invention relates to a method for preparing the composition, comprising the steps of culturing the fetus-derived mesenchymal stem cells in amniotic fluid; and collecting the culture medium.

Formulations of human amniotic fluid and methods of use thereof for treatment of lung disorders, and / or injuries have been developed. The formulations are suitable for topical delivery to the lung for treatment of lung disorders including chronic obstructive pulmonary disorders (COPD), asthma, emphysema, bronchiectasis, chronic bronchitis, interstitial lung disease, alpha-1 antitrypsin emphysema, as well as for treatment of acute lung injuries. Methods including administering specifically formulated, diluted sterile de-cellularized human amniotic fluids topically to the lungs, preferably as aerosol droplets, are described. In particular, the methods involving administration of the amniotic fluid formulation in the form of aerosol droplets with size between about 1.5 μm to about 5 μm, preferably from about 2.5 μm to about 3.5 μm, inclusive, using apparatus such as high-efficiency vibrating mesh nebulizers, are described. Formulations described can treat, or prevent one or more symptoms of a chronic lung disorder.

The invention discloses an amniotic fluid protein prediction method based on a recurrent neural network, and belongs to the technical field of big data and artificial intelligence. According to the method, a protein list verified by biological experiments in amniotic fluid of existing literatures and databases is used as a positive sample for model training; protein family information corresponding to the positive sample is deleted from a Pfam protein family information database, protein families with the number of proteins exceeding 5 in the families are searched for in the remaining proteinfamily information database, and five pieces of protein information are randomly selected from the protein families to serve as negative samples for model training. The method further comprises the steps of: dividing the positive sample data and the negative sample data into a training set, a verification set and a test set; and carrying out feature selection on protein features, building a model,training the model by using the training set, carrying out parameter adjustment on the verification set, and carrying out performance evaluation on the test set. The input is a protein feature and the output is a prediction result. The accuracy of amniotic fluid prediction is improved, and finally amniotic fluid protein prediction is achieved.

The invention provides an SNP locus for detecting an acute hemolytic transfusion reaction caused by a variant gene FUT1 of an H blood-group system, that is a new GA deletion mutation of 550th base and551th base from an initiation codon of an H-type variant gene encoding region. The invention provides new use of the variant gene FUT1 so as to provide an effective rapid gene diagnosis, gene screening and genetic counseling way for induced acute intravascular hemolytic transfusion reactions; proven by an application effect, the genic SNP locus and detection primers provided by the invention canbe used for effectively carrying out rapid detection on new H blood-group system variant gene mutant sites of peripheral blood and fetal villi or amniotic fluid of patients in clinical.